Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F 573

Next Previous
Drug Profile

F 573

Alternative Names: CV-1013; EP-1013; F-573; MX-1013

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Gyre Therapeutics
  • Class Antineoplastics; Dipeptides; Small molecules
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver failure
  • No development reported Transplant rejection; Viral hepatitis
  • Discontinued Liver disorders; Multiple organ failure; Myocardial infarction; Septic shock; Stroke

Most Recent Events

  • 31 Dec 2023 Gyre Therapeutics has two patents protection in the People's Republic of China (PRC) for F 573 (Gyre Therapeutics 10-K, April 2024)
  • 31 Dec 2023 Gyre Therapeutics has one patent pending application and one Patent Cooperation Treaty (PCT) patent applicationin the People's Republic of China (PRC) for F 573 (Gyre Therapeutics 10-K, April 2024)
  • 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top